Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well nintedanib works in treating patients with
neuroendocrine tumors that have spread from where they started to nearby tissue or lymph
nodes (locally advanced) or have spread from the primary site (place where they started) to
other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by
slowing or stopping a certain type of receptor called vascular endothelial growth factor
receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine
tumors by blocking the growth of new blood vessels necessary for tumor growth.